10-Q: Cencora Q3 Earnings Soar on Strong US Healthcare Growth

Cencora reports significant revenue and profit increases, driven by the acquisition of Retina Consultants of America and strong GLP-1 product sales, despite a notable decline in operating cash flow.

Summary

• Revenue increased by 8.7% to $80.66 billion for the three months ended June 30, 2025, and by 10.6% to $237.60 billion for the nine months ended June 30, 2025, compared to the prior year periods.
• Net income attributable to Cencora, Inc. rose 42.2% to $687.4 million for the quarter and 25.8% to $1.89 billion for the nine-month period.
• Diluted earnings per share (EPS) increased by 45.5% to $3.52 for the quarter and 29.5% to $9.70 for the nine-month period.
• The U.S. Healthcare Solutions segment saw revenue growth of 8.5% for the quarter and 11.1% for the nine-month period, primarily due to overall market growth and increased sales of GLP-1 class products.
• Sales of GLP-1 class products, used for diabetes and/or weight loss, increased by $1.4 billion (18.6%) for the quarter and $6.8 billion (34.4%) for the nine-month period.
• The company acquired an 85% interest in Retina Consultants of America (RCA) on January 2, 2025, for approximately $4.04 billion in cash, contributing $1.4 billion in revenue since the acquisition date.
• Cash provided by operating activities decreased significantly by $1.7 billion to $741.7 million for the nine months ended June 30, 2025, primarily due to changes in working capital accounts.
• Total debt increased to $8.24 billion as of June 30, 2025, from $4.39 billion as of September 30, 2024, largely due to financing the RCA acquisition and general corporate purposes.
• The company's accrued litigation liability related to opioid settlements was $4.7 billion as of June 30, 2025, with an estimated $416.8 million to be paid prior to June 30, 2026.
• A proposed class action settlement agreement was reached with third-party payors for opioid-related claims, with final approval granted on January 15, 2025, and a subsequent appeal settlement on June 12, 2025.
• A proposed class action settlement agreement was also reached with hospitals for opioid-related claims, with final approval granted on April 4, 2025.
• The company recognized gains from antitrust litigation settlements of $9.5 million for the quarter and $231.0 million for the nine-month period.
• Quarterly cash dividends increased by 8% to $0.55 per share in November 2024.

Sentiment

Score: 8

Explanation: The company demonstrates strong financial performance with significant revenue and profit growth, driven by strategic acquisitions and market trends. While there's a notable decrease in operating cash flow and an increase in debt, these are largely attributable to acquisition financing and working capital timing, which the company appears to be actively managing. The ongoing opioid litigation, while material, is being addressed through settlements. The overall outlook for core business performance and strategic expansion is positive.

Positives

• Strong revenue growth of 8.7% for the quarter and 10.6% for the nine-month period, driven by both U.S. and International Healthcare Solutions segments.
• Significant increase in net income attributable to Cencora, Inc. by 42.2% for the quarter and 25.8% for the nine-month period.
• Diluted EPS saw substantial growth of 45.5% for the quarter and 29.5% for the nine-month period.
• U.S. Healthcare Solutions segment demonstrated robust performance with 8.5% revenue growth and 29.1% operating income growth for the quarter, largely due to market expansion and the RCA acquisition.
• Sales of GLP-1 class products (diabetes/weight loss) contributed significantly to growth, increasing by $1.4 billion (18.6%) for the quarter and $6.8 billion (34.4%) for the nine-month period.
• Gross profit increased by 20.6% for the quarter and 14.9% for the nine-month period, with U.S. Healthcare Solutions' gross profit rising 31.3% for the quarter.
• Operating income increased by 29.0% for the quarter and 27.4% for the nine-month period, reflecting improved operating leverage.
• Successful acquisition of Retina Consultants of America (RCA) on January 2, 2025, which is expected to broaden relationships with community providers and build leadership in specialty pharmaceuticals.
• Company successfully amended and restated its Multi-Currency Revolving Credit Facility, extending its expiration to June 2030 and increasing commitments to $4.5 billion, enhancing liquidity.
• Receivables Securitization Facility was extended to June 2028 and increased to $1.5 billion, further strengthening liquidity.
• Increased quarterly cash dividend by 8% to $0.55 per share, demonstrating commitment to shareholder returns.
• Realized significant gains from antitrust litigation settlements, totaling $231.0 million for the nine-month period.
• Improved working capital metrics with Days Sales Outstanding (DSO) decreasing to 27.9 days from 29.0 days, and Days Payable Outstanding (DPO) decreasing to 59.0 days from 60.1 days for the three months ended June 30, 2025.

Negatives

• Cash provided by operating activities decreased significantly by $1.7 billion for the nine months ended June 30, 2025, primarily due to unfavorable changes in working capital accounts, including increases in accounts receivable and inventories.
• Total debt increased substantially to $8.24 billion as of June 30, 2025, from $4.39 billion as of September 30, 2024, leading to a 161.1% increase in net interest expense for the quarter and 57.1% for the nine-month period.
• International Healthcare Solutions' operating income decreased by 12.9% for the quarter and 11.1% for the nine-month period, primarily due to lower operating income at global specialty logistics and specialized consulting services businesses.
• Lower LIFO credit in the current nine-month period compared to the prior year period, primarily due to slightly higher brand pharmaceutical inflation.
• Ongoing litigation and opioid-related expenses, including a $74 million jury verdict against AmerisourceBergen Drug Corporation in Maryland, though a new trial on damages or remittitur to $14.4 million was granted.
• Potential goodwill impairment for the PharmaLex reporting unit in the fourth quarter of fiscal 2025, which had goodwill of $723.9 million as of June 30, 2025.
• Increased capital expenditures by $113.3 million to $418.2 million for the nine months ended June 30, 2025.
• Reduced common stock repurchases to $435.4 million for the nine months ended June 30, 2025, compared to $986.4 million in the prior year period.

Risks

• Ability to respond to general macroeconomic conditions and geopolitical uncertainties, including financial market volatility, inflation, interest and currency exchange rates, and changes from the U.S. presidential election.
• Retention of key customer or supplier relationships under less favorable economics or adverse resolution of contract disputes.
• Competition and industry consolidation leading to increased pressure to reduce prices for products and services.
• Risks associated with the strategic relationship with Walgreens Boots Alliance, Inc. (WBA), including pharmaceutical distribution and global generic purchasing agreements.
• Acquisitions (e.g., Alliance Healthcare, PharmaLex, RCA) and investments (e.g., OneOncology) may fail to achieve expected financial and operating performance.
• Ability to effectively manage growth, including integration of acquired businesses.
• Maintaining the strength and security of information technology systems and anticipating/detecting data or information security breaches or cyber-attacks.
• Managing foreign expansion, including compliance with U.S. Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions, and import regulations.
• Financial and other impacts of macroeconomic and geopolitical trends and events on international operations, including conflicts in Ukraine and between Israel and Hamas.
• Changes or uncertainty in geopolitical policies, trade policies, or tariffs that can disrupt global operations.
• Unfavorable trends in brand and generic pharmaceutical pricing, including rate or frequency of price inflation or deflation.
• Changes in the U.S. healthcare and regulatory environment, including impacts on prescription drug reimbursement under Medicare and Medicaid and declining reimbursement rates.
• Bankruptcy, insolvency, or other credit failure of a major supplier or significant customer.
• Ability to comply with increasing governmental regulations regarding the pharmaceutical supply chain.
• Continued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances and diversion.
• Uncertainties associated with litigation, including the outcome of legal or governmental proceedings, and potential for material adverse resolution of pending legal proceedings.
• Risks generally associated with data privacy regulation and the protection and international transfer of personal data.
• Events outside of company control, such as widespread public health issues, natural disasters, government policy changes, and political events.
• Impairment of goodwill or other intangible assets resulting in a charge to earnings, specifically noted for the PharmaLex reporting unit.

Future Outlook

The company anticipates continued revenue growth influenced by industry trends, including GLP-1 drug utilization, new brand therapies, and the introduction of generics/biosimilars. It expects to invest approximately $600 million in capital expenditures during fiscal 2025, focusing on expanding and enhancing its distribution network and technology initiatives. The company believes future cash flows from operations and borrowings will be sufficient to fund ongoing cash requirements, including opioid litigation payments over the next 14 years. The company is evaluating the potential for goodwill impairment for the PharmaLex reporting unit in the fourth quarter of fiscal 2025.

Management Comments

• Future revenue growth will continue to be affected by various factors, such as industry growth trends, including drug utilization (e.g., products labeled for diabetes and/or weight loss in the GLP-1 class), the introduction of new, innovative brand therapies and vaccines, and the likely increase in generic drugs and biosimilars.
• The company expects to invest approximately $600 million in capital expenditures during fiscal 2025, with a focus on expanding and enhancing its distribution network and various technology initiatives.
• Future cash flows from operations and borrowings are expected to be sufficient to fund ongoing cash requirements, including the opioid litigation payments that will be made over the next 14 years.

Industry Context

Cencora's strong performance, particularly in its U.S. Healthcare Solutions segment, aligns with broader industry trends of increasing demand for specialty pharmaceuticals and the significant impact of new drug classes like GLP-1 products for diabetes and weight loss. The acquisition of Retina Consultants of America indicates a strategic move to deepen relationships with community providers and expand its leadership in specialty areas. The ongoing opioid litigation reflects a persistent challenge across the pharmaceutical distribution industry, requiring substantial financial provisions and legal management. The company's ability to secure and expand credit facilities amidst rising interest rates demonstrates its financial resilience in a dynamic healthcare market.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess against global benchmarks.

Corporate Governance

Legal Proceedings

• Opioid lawsuits and investigations: Numerous lawsuits from counties, municipalities, states, and tribes against pharmaceutical wholesale distributors, including Cencora, related to prescription opioid pain medications.
• Distributor Settlement Agreement: Effective April 2, 2022, resolving a substantial majority of opioid lawsuits from state and local governmental entities, covering 48 of 49 eligible states and 99% of eligible political subdivisions. Accrued liability of $4.7 billion as of June 30, 2025, to be paid over 14 years.
• Maryland Public Nuisance Trial: Jury verdict on November 12, 2024, finding AmerisourceBergen Drug Corporation (ABDC) liable for public nuisance, assessing approximately $74 million in compensatory damages against ABDC. Court upheld liability but granted a new trial on damages or remittitur to $14.4 million. Ruling on abatement remedy expected by August 8, 2025.
• Third-Party Payors Settlement: Proposed class action settlement agreement reached on August 29, 2024, to resolve opioid-related claims of a putative class of third-party payors, with a $93.0 million litigation expense accrual. Final approval granted January 15, 2025. An appeal was filed on February 13, 2025, and a settlement with the sole objector was entered into on June 12, 2025, pending MDL Court approval.
• Hospitals Settlement: Proposed class action settlement agreement reached on September 26, 2024, to resolve opioid-related claims of a proposed class of hospitals, with a $120.9 million litigation expense accrual. Final approval granted April 4, 2025.
• Department of Justice Civil Complaint: Filed December 29, 2022, against the company and subsidiaries, alleging violations of the Controlled Substances Act for negligently failing to report suspicious orders. Claims for civil penalties prior to October 24, 2018, were dismissed. Fact discovery deadline is June 12, 2026, and expert discovery deadline is January 15, 2027. The company denies allegations and intends to defend vigorously.
• Shareholder Securities Litigation: Derivative action filed December 30, 2021, alleging breach of fiduciary duty related to controlled substance diversion control programs. Initially dismissed, then reversed on appeal. An agreement in principle to settle all claims was reached on July 28, 2025, pending court approval.
• MWI Veterinary Supply Co. Criminal Investigation: U.S. Attorneys Office for the Western District of Virginia notified the company of a criminal investigation into its animal health subsidiary regarding compliance with regulatory requirements for wholesale shipments. An agreement in principle to resolve these claims was reached in October 2024, with a $49.1 million litigation expense accrual.

Related Party Transactions

• The acquisition of Retina Consultants of America (RCA) included a $545.7 million settlement of a net receivable resulting from a pre-existing commercial relationship between Cencora and RCA.

Stakeholder Impact

• Shareholders: Positive impact from increased net income, EPS, and dividend. Share repurchase program continues to return capital, though at a slower pace. Increased debt and ongoing litigation present financial risks.
• Employees: Workforce reductions occurred in both reportable segments as part of restructuring and employee severance costs. Share-based compensation expense continues.
• Customers: Increased sales of specialty products and GLP-1 drugs indicate strong customer demand. Termination of a sales contract with an oncology customer highlights contract renewal risks.
• Suppliers: Changes to manufacturer pricing and distribution policies, as well as the bankruptcy/insolvency of a major supplier, could impact operations.
• Creditors: Increased debt levels and interest expense, but the company has successfully amended and extended credit facilities, demonstrating continued access to capital. Compliance with debt covenants is maintained.

Next Steps

• The City of Baltimore must elect to either accept the reduced damages award or proceed with a new trial in the Maryland opioid case.
• The Court intends to issue its ruling in the second phase of the Maryland opioid trial regarding the City of Baltimore's request for abatement by August 8, 2025.
• The settlement with the sole objector to the third-party payors opioid settlement is currently pending approval from the MDL Court.
• The company will continue to litigate and prepare for trial, and vigorously defend itself in all opioid-related matters not yet settled.
• Fact discovery for the Department of Justice's civil complaint alleging Controlled Substances Act violations is set for June 12, 2026, with expert discovery by January 15, 2027.
• The Special Litigation Committee's agreement in principle to settle the shareholder securities litigation is pending the Court's approval.
• Company management is in the early stages of updating estimated financial projections for all business units to complete annual goodwill impairment testing in the fourth quarter of fiscal 2025.
• The company expects to invest approximately $600 million in capital expenditures during fiscal 2025, focusing on distribution network expansion and technology initiatives.
• The company expects to pay the remaining $57.9 million related to the 2017 Tax Act transition tax commitment in January 2026.
• The Working Capital Credit Facility expires in July 2026.

Key Dates

Recommendation

Cencora's Q3 2025 results demonstrate robust top-line and bottom-line growth, significantly boosted by the strategic acquisition of Retina Consultants of America and strong demand for GLP-1 products. While the substantial increase in debt and the decline in operating cash flow are notable, they are largely attributable to the financing of the RCA acquisition and working capital timing, which the company is actively managing through extended credit facilities. The ongoing opioid litigation, though a material liability, is being systematically addressed through settlements, reducing long-term uncertainty. The company's commitment to shareholder returns, evidenced by an increased dividend and continued share repurchases, further supports a positive outlook. Given the strong underlying business performance, strategic expansion into high-growth areas, and effective management of financial obligations, Cencora presents a compelling long-term investment opportunity despite the increased leverage.

Keywords

Healthcare Distribution, Pharmaceuticals, Drug Distribution, Specialty Pharmaceuticals, GLP-1, Retina Consultants of America, Acquisition, SEC Filing, 10-Q, Financial Results, Opioid Litigation, Supply Chain, Corporate Debt, Share Repurchase, Dividends